You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • FRI0091 Australian economic evaluation of tocilizumab monotherapy vs adalimumab monotherapy in patients with rheumatoid arthritis based on the adacta trial

Article metrics

Article menu
Download PDFPDF
Poster Presentation
Rheumatoid arthritis - prognosis, predictors and outcome
FRI0091 Australian economic evaluation of tocilizumab monotherapy vs adalimumab monotherapy in patients with rheumatoid arthritis based on the adacta trial

 

Online download statistics by month:

Online download statistics by month: February 2014 to March 2024

AbstractFullPdf
Feb 20141402
Mar 2014501
Apr 2014200
May 2014701
Jul 2014300
Aug 2014400
Oct 2014802
Nov 2014601
Dec 2014200
Jan 20151502
Feb 2015200
Mar 20151901
Apr 2015600
May 2015201
Jul 2015600
Aug 2015200
Sep 2015500
Oct 2015501
Nov 2015402
Dec 2015702
Jan 2016802
Feb 2016001
Mar 2016300
Apr 20161501
May 20161200
Jun 2016500
Jul 2016800
Aug 2016300
Sep 2016400
Oct 2016700
Nov 2016500
Dec 2016300
Jan 2017600
Feb 2017100
Mar 2017900
Apr 2017600
May 2017702
Jun 2017500
Jul 2017200
Aug 2017600
Sep 20171000
Oct 20172002
Nov 2017200
Dec 20171200
Jan 20181400
Feb 2018200
Mar 2018800
Apr 20182001
May 20184801
Jun 2018600
Jul 2018800
Aug 20181600
Sep 20182200
Oct 2018201
Nov 2018800
Dec 2018800
Feb 2019800
Mar 2019200
Apr 2019400
May 2019802
Jun 2019200
Jul 2019400
Aug 20191201
Sep 2019600
Nov 2019500
Dec 2019600
Feb 2020200
Mar 2020600
Apr 2020801
May 2020200
Jun 2020400
Jul 2020200
Aug 20201200
Sep 2020900
Oct 2020400
Nov 2020400
Dec 2020200
Jan 2021600
Feb 2021200
Mar 2021400
Apr 2021400
Jun 2021500
Aug 2021200
Oct 2021900
Nov 2021400
Dec 2021800
Feb 2022200
Mar 20221400
Apr 20224400
May 2022600
Jun 2022400
Jul 20221200
Aug 2022800
Sep 20221000
Oct 2022400
Nov 2022400
Dec 2022800
Jan 2023200
Feb 2023400
Mar 2023200
May 2023600
Jul 2023200
Aug 2023200
Sep 2023600
Nov 2023200
Dec 2023600
Mar 20241800
Total767031